immune checkpoint inhibition trials in mcc: advanced ... · presented by selma ugurel at 2018 asco...

Immune Checkpoint Inhibition Trials in MCC:<br />Advanced Metastatic Disease

Presented By Selma Ugurel at 2018 ASCO Annual Meeting

Immune Checkpoint Inhibition Trials in MCC:<br />Advanced Metastatic Disease

Presented By Selma Ugurel at 2018 ASCO Annual Meeting

Overall survival with pembrolizumab for MCC <br />

Presented By Paul Nghiem at 2018 ASCO Annual Meeting

Anti-PD-1/PD-L1 in advanced MCC: <br />first-line or second-line (chemo-naïve or chemo-pretreated) ?

Presented By Selma Ugurel at 2018 ASCO Annual Meeting

Anti-PD-1/PD-L1 in advanced MCC: <br />first-line or second-line (chemo-naïve or chemo-pretreated) ?

Presented By Selma Ugurel at 2018 ASCO Annual Meeting

Durable response on anti-PD-1/PD-L1 ?

Presented By Selma Ugurel at 2018 ASCO Annual Meeting

Which patterns of resistance do we see ?

Presented By Selma Ugurel at 2018 ASCO Annual Meeting

Radiologic tumor response to pembrolizumab in patients<br />per viral status<br /><br /><br />

Presented By Paul Nghiem at 2018 ASCO Annual Meeting